The University of Texas MD Anderson Cancer Center today was awarded 15 grants totaling $19.38 million from the Cancer Prevention and Research Institute of Texas (CPRIT) in support of cancer research projects across the institution. “We are grateful for CPRIT’s invaluable support of MD Anderson’s mission to end cancer,” said Peter Pisters, M.D., president of MD Anderson. “The funds awarded today will strengthen the ability of our world-leading team of dedicated scientists and clinicians to […]
MD Anderson
Neoadjuvant Immunotherapy With Relatlimab And Nivolumab Is Safe And Effective In Stage Iii Melanoma
Study provides further evidence for pre-surgery immune checkpoint inhibitors in operable skin cancer Giving the combination of immune checkpoint inhibitors relatlimab and nivolumab to patients with stage III melanoma before surgery was safe and completely cleared all viable tumor in 57% of patients in a Phase II study, researchers from The University of Texas MD Anderson Cancer Center reported in Nature today. In addition to meeting the primary endpoint of pathologic complete response (pCR), the overall pathologic response rate (up to 50% of […]
CPRIT awards $2.5 million to support MD Anderson cancer research
The University of Texas MD Anderson Cancer Center was awarded $2.5 million today from the Cancer Prevention and Research Institute of Texas (CPRIT) to support cancer research projects across the institution. Four of the five grants awarded to MD Anderson today are CPRIT High-Impact/High-Risk Research Awards, which provide short-term funding to explore the feasibility of high-risk projects that, if successful, would contribute major new insights into the etiology, diagnosis, treatment or prevention of cancers. “We are […]
MD Anderson receives CPRIT funding to expand access to cervical cancer screening and treatment in Texas
The University of Texas MD Anderson Cancer Center today was awarded $2.5 million in continued funding from the Cancer Prevention and Research Institute of Texas (CPRIT) to support the expansion of cervical cancer prevention services to rural and medically underserved populations. While cervical cancer rates have fallen by 70% in the U.S. due to widespread use of screening tests that help doctors find and treat precancerous cells, cervical cancer remains a challenge in areas with limited access to screening […]
MD Anderson named #1 in the nation for cancer care
The University of Texas MD Anderson Cancer Center today was named number one in the nation for cancer care in U.S. News & World Report’s 2022-23 “Best Hospitals” rankings. The institution has been one of the nation’s top two hospitals for cancer care since the survey’s inception in 1990. “We are proud to be ranked as the nation’s leader in cancer care,” said Peter WT Pisters, M.D., president of MD Anderson. “This ongoing recognition is thanks to the incredible […]
Md Anderson And BostonGene Announce Strategic Alliance To Advance Personalized Cancer Diagnostics And Treatments
The University of Texas MD Anderson Cancer Center and BostonGene Corporation today announced a strategic alliance to advance the development and clinical integration of multiplatform biomarker signatures. The alliance brings together BostonGene’s innovative computational platform and CLIA-certified and CAP-accredited high complexity molecular laboratory with the clinical and translational research expertise of MD Anderson, leveraging scientific discovery, analytical advancement and powerful computing to develop clinically applicable solutions for patients with cancer. BostonGene’s computational platform evaluates myriad molecular and immune-based parameters […]
Md Anderson Celebrates World Cancer Research Day, Progress Made To End Cancer Through Research
The University of Texas MD Anderson Cancer Center is proud to support World Cancer Research Day, Sept. 24, and its efforts to promote cancer research as a driving force behind progress in cancer prevention, early detection, treatment and survivorship. World Cancer Research Day, a global collaboration launched in 2016 by 10 institutions, is focusing this year on the theme “Cancer Research Works: Driving Progress Together.” More than 115 organizations, including MD Anderson, have signed on to support […]
MD Anderson Research Highlights: ESMO 2021 Special Edition
Key presentations to focus on novel cell therapies, antibody-drug conjugates and neoadjuvant immunotherapy The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent studies in basic, translational and clinical cancer research from MD Anderson experts. This special edition features oral presentations by MD Anderson researchers at the virtual European Society for Medical Oncology (ESMO) Congress 2021 on novel therapeutic approaches, including cell therapy for solid tumors, antibody drug conjugates targeting TROP2 and […]
MD Anderson researchers present new findings in targeted and combination therapies at 2021 ASCO Annual Meeting
Several Phase II clinical trials conducted by researchers from The University of Texas MD Anderson Cancer Center show promising results for patients with melanoma, breast cancer, HER2-positive tumors and ovarian cancer. The results of these studies, which will be presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, highlight new advances in drug therapy research to improve patient outcomes. Combination therapy of nivolumab and relatlimab before and after surgery is effective against melanoma (Abstract […]
Metabolic Inhibitor Iacs-6274 Shows Early Antitumor Effects In Underserved Patients With Advanced Cancers
Drug developed by MD Anderson’s Therapeutics Discovery division is well-tolerated with effective glutaminase inhibition in Phase I trial The glutaminase (GLS1) inhibitor IACS-6274, discovered and developed by The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery division, appears to be well-tolerated with successful target inhibition and early signs of anti-tumor activity in a biomarker-driven Phase I trial. Interim results of the study will be presented at the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting on June […]